#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15894	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2310	839.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1799	1799	T	992	T,G	988,4	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15894	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2310	839.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1533	1533	C	1034	C,T,A	1031,1,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15894	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2310	839.3	0	HET	.	.	.	A69G	.	69	69	A	418	418	A	1035	A,G	823,211	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15894	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2310	839.3	0	HET	.	.	.	C262T,G	.	262	262	C	611	611	C	932	C,T,G	714,217,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27084	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4047	834.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1926	1926	A	1131	A,C	1130,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27084	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4047	834.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2560	2560	C	941	C,G,A	937,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27084	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4047	834.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2634	2634	A	776	A	776	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27084	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4047	834.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3186	3186	C	997	C,A	996,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2354	folP	852	852	99.88	folP.l15.c4.ctg.1	1993	147.3	0	.	p	.	0	E151K	NONSYN	451	453	GAA	988	990	AAA	230;224;225	A;A;A	230;224;225	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2354	folP	852	852	99.88	folP.l15.c4.ctg.1	1993	147.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1219	1221	AGC	263;264;267	A;G;C,G	263;264;266,1	folP.WHO_W_01420c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5856	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3955	184.5	1	SNP	p	S91F	0	.	.	271	273	TCC	875	877	TCC	200;200;199	T,G;C;C	199,1;200;199	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5856	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3955	184.5	1	SNP	p	D95G	0	.	.	283	285	GAC	887	889	GAC	208;208;208	G;A;C	208;208;208	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5856	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3955	184.5	1	SNP	p	D95N	0	.	.	283	285	GAC	887	889	GAC	208;208;208	G;A;C	208;208;208	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	2174	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1859	145.9	1	SNP	p	G45D	0	.	.	133	135	GGC	730	732	GGC	239;239;237	G,A;G;C	238,1;239;237	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1132	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1342	104.7	0	.	n	.	0	A197.	DEL	197	197	A	702	702	A	235	A	235	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5578	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3388	205.4	1	SNP	p	D86N	0	.	.	256	258	GAC	794	796	GAC	248;250;250	G;A;C	248;250;250	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5578	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3388	205.4	1	SNP	p	S87R	0	.	.	259	261	AGT	797	799	AGT	247;247;246	A,T;G;T,G	246,1;247;245,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5578	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3388	205.4	1	SNP	p	S87W	0	.	.	259	261	AGT	797	799	AGT	247;247;246	A,T;G;T,G	246,1;247;245,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5578	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3388	205.4	1	SNP	p	S87I	0	.	.	259	261	AGT	797	799	AGT	247;247;246	A,T;G;T,G	246,1;247;245,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5578	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3388	205.4	1	SNP	p	S88P	0	.	.	262	264	TCC	800	802	TCC	248;248;246	T,G;C;C	246,2;248;246	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4692	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3102	188.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1746	1748	GGC	258;258;258	G;G;C	258;258;258	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1409	1411	GCA	243;242;243	G;C,A;A,G,C	243;241,1;241,1,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1412	1414	ATC	241;239;240	A;T;C	241;239;240	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1424	1426	GTG	243;244;244	G;T;G	243;244;244	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1424	1426	GTG	243;244;244	G;T;G	243;244;244	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1928	1930	ACC	253;255;254	A,G;C,T;C	252,1;254,1;254	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1982	1984	GCG	247;244;246	G;C,G;G,T,C	247;242,2;244,1,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1982	1984	GCG	247;244;246	G;C,G;G,T,C	247;242,2;244,1,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2105	2107	GGC	226;225;227	G;G;C	226;225;227	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2114	2116	GGC	225;224;221	G;G;C	225;224;221	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4262	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2855	186.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2132	2134	CTG	216;215;218	C,G;T,G;G,C	215,1;214,1;217,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6154	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3734	205.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1961	1963	CCG	256;256;255	C,T;C;G	255,1;256;255	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2556	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2215	143.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	744	744	C	201	C	201	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	286	porB1a	984	93	94.62	porB1a.l15.c17.ctg.1	177	52.7	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	64;60;55	A;C,T;G	64;59,1;55	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	286	porB1a	984	156	92.95	porB1a.l15.c17.ctg.3	156	48.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	23;27;27	T;T;A	23;27;27	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	286	porB1a	984	156	92.95	porB1a.l15.c17.ctg.3	156	48.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	60;60;60	C;A;T	60;60;60	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	286	porB1a	984	156	92.95	porB1a.l15.c17.ctg.3	156	48.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	60;60;60	A;G;T	60;60;60	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	286	porB1a	984	156	92.95	porB1a.l15.c17.ctg.3	156	48.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	60;60;60	T;A;C	60;60;60	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	2071	179.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	685	687	GAA	276;273;271	G;A;A	276;273;271	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	2071	179.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	973	975	GAT	259;259;259	G,T;A,T;T	258,1;258,1;259	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	2071	179.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1096	1098	TCA	256;255;258	T;C;A	256;255;258	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	2071	179.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1225	1227	GTC	251;254;253	G;TCCCC,TCCC;C	251;237,1;253	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	2071	179.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1555	1557	GCA	256;256;258	G;C;A	256;256;258	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	2071	179.3	1	SNP	p	G120K	1	.	.	358	360	AAG	931	933	AAG	246;247;248	A,C;A;G	245,1;247;248	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	2071	179.3	1	SNP	p	D121N	0	.	.	361	363	GAC	934	936	GAC	250;253;254	G;A,C;C	250;252,1;254	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	2071	179.3	1	SNP	p	A121D	1	.	.	361	363	GAC	934	936	GAC	250;253;254	G;A,C;C	250;252,1;254	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10720	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5276	253.3	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2238	2240	AAT	292;290;292	A;A;T,A	292;290;291,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1670	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1541	135.1	1	SNP	p	V57M	1	.	.	169	171	ATG	806	808	ATG	285;285;285	A,C;T;G	283,2;285;285	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
